Skip to main content
. 2019 Jul 8;10(7):520. doi: 10.1038/s41419-019-1749-0

Fig. 6. CTRP3 alleviates PE-induced cardiomyocyte hypertrophy in vitro by inhibiting the p38 MAPK pathway.

Fig. 6

a Representative western blot (left) and quantification (right) of the p38-CREB signaling pathway activity in NRCMs from the indicated groups (n = 5 samples per group). b Representative western blot (left) and quantification (right) of the p38-CREB signaling pathway activity in NRCMs from the indicated groups (n = 5 samples per group). c Left: Representative immunofluorescence images of NRCMs transfected with siRNA or si-CTRP3, and stained with α-actinin (red) and DAPI (blue). The NRCMs were treated with dimethyl sulfoxide (DMSO) or a p38 inhibitor SB203580 (1 μM). Right: The mean cell surface area of NRCMs in the indicated groups (n ≥ 30 cells per group). d Real-time PCR analysis of the expression of genes encoding the hypertrophic markers β-MHC, ANP, and BNP in the indicated groups (n = 5 samples per group). e Representative western blot (left), and quantification (right) of p-CREB and CREB levels in NRCMs from the indicated groups (n = 5 samples per group). f Left: Representative immunofluorescence images of PBS- and CTRP3-treated NRCMs stained with α-actinin (red) and DAPI (blue). The NRCMs were treated with DMSO or SB203580 (1 μM). Right: The mean cell surface area of NRCMs in the indicated groups (n ≥ 30 cells per group). g Real-time PCR analysis of the expression of genes encoding the hypertrophic markers β-MHC, ANP, and BNP in the indicated groups (n = 4 samples per group). h Representative western blot (left), and quantification (right) of p-CREB and CREB levels in NRCMs from the indicated groups (n = 5 samples per group). The data were analyzed by one-way ANOVA. a, and b *p < 0.05, **p < 0.01 vs. control, #p < 0.05 vs. PE. e, h *p < 0.05 between the two indicated groups; ns, not significant. In the bar graphs, the data are presented as the mean ± SEM